Mesoblast Limited (MESO) Fair Value & Analysis
Healthcare · US · Market cap $1.9B
Mesoblast Limited
MESO · US
Fair value as of: Jun 24, 2026
From 2 valuation models · updated 6 days ago
Share price −12.1% over the past month.
Price vs Fair Value (12 months)
12‑month range $11.88 – $23.83 · fair‑value band $15.60 – $25.99 · the $15.38 price screens below the $20.80 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Mesoblast Limited (MESO) currently trades at $15.38, while our model-based Fair Value estimate is $20.80 — implying the stock looks roughly 35.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Trailing-twelve-month revenue stands at $65.4M. It earns a return on equity of -18.2%. The balance sheet holds a net cash position of $33.0M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-I…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Mesoblast Limited reported revenue of $17.2M in FY2025 versus $7.5M in FY2021, a compound +23.2%/yr. Reported net income was −$102M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $288.18 | $51.70 | -82% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Mesoblast Limited (MESO) undervalued?
What is the fair value of MESO?
What is the quality score of MESO?
What is the revenue of Mesoblast Limited (MESO)?
What is the net profit margin of MESO?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.